Catalog No.
Product Name
Application
Product Information
Citations
-
AMPK Activator
3α-Hydroxymogrol is a triterpenoid derived from Siraitia grosvenorii Swingle, recognized for its ability to activate AMP-activated protein kinase (AMPK). This compound promotes phosphorylation of AMPK, which plays a critical role in cellular energy homeostasis. Research applications include studying metabolic disorders, energy regulation, and potential therapeutic effects in obesity and diabetes. -
AMPK Activator
IQZ23 is an AMPK activator that inhibits adipocyte differentiation through the activation of the AMPK pathway. It demonstrates potent efficacy in reducing triglyceride levels, with an EC50 of 0.033 μM in 3T3-L1 adipocytes. This compound is relevant for research into obesity and associated metabolic disorders, making it a valuable tool for studying metabolic regulation. -
mTOR Inhibitor/AMPK Activator
AMPK/mTOR modulator-1 is a Ginsenoside derivative functioning as both an mTOR inhibitor and AMPK activator. It activates AMPK signaling with a Kd of 4.759 μM, promoting M1-like tumor-associated macrophage polarization while inhibiting M2-like polarization. This compound enhances glycolysis and demonstrates significant anti-inflammatory activity alongside inhibition of tumor progression. AMPK/mTOR modulator-1 is ideal for research focused on colorectal cancer and related metabolic disorders. -
AMPK Activator
AMPK Activator 9 (ZM-6) is a potent activator of AMP-activated protein kinase (AMPK) with an EC50 value of 1.1 µM, primarily targeting the α2β1γ1 subunit. This compound demonstrates significant biological activity in energy metabolism modulation and has applications in research focused on type 2 diabetes. It serves as a valuable tool for elucidating AMPK-related pathways and therapeutic strategies for metabolic disorders. -
AMPK Activator
AMPK activator 8 is a potent activator of AMP-activated protein kinase (AMPK), demonstrating EC50 values of 11, 27, 4, 2, and 4 nM for various AMPK isoforms: rAMPK α1β1γ1, rAMPK α2β1γ1, rAMPK α1β2γ1, rAMPK α2β2γ1, and rAMPK α2β2γ3. This compound is particularly valuable for studying metabolic disorders, specifically type 2 diabetes, by enhancing AMPK activity and modulating glucose metabolism. Its high specificity and efficacy make it an important tool for researchers exploring AMPK-related pathways and therapeutic interventions. -
AMPK Activator
AMPK Activator 6 is a potent activator of AMP-activated protein kinase (AMPK) that enhances its signaling pathway in HepG2 and 3T3-L1 cells. This compound effectively reduces lipid accumulation by significantly lowering triglyceride (TG), total cholesterol (TC), and low-density lipoprotein-C (LDL-C) levels in serum. AMPK Activator 6 is valuable for research into non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome, making it a critical tool for investigating metabolic disorders. -
AMPK Activator
AMPK Activator 10 is a potent activator of AMP-activated protein kinase (AMPK) with an effective concentration (EC150) of 44.3 nM as determined by cell-ELISA. This compound enhances phosphorylation of acetyl-CoA carboxylase (ACC), contributing to its biological effects. AMPK Activator 10 has demonstrated glucose-lowering properties, making it a valuable tool for research in metabolic regulation and related disorders. -
AMPK Activator
JJO-1 is an activator of AMP-activated protein kinase (AMPK) with an EC50 of 1.8 μM. This compound is valuable for research into metabolic disorders, particularly obesity and type 2 diabetes, as it modulates energy homeostasis and enhances glucose uptake. JJO-1 provides a tool for scientists investigating therapeutic strategies aimed at metabolic regulation and improving insulin sensitivity. -
CB1R/AMPK Modulator
CB1R/AMPK Modulator 1 is a potent modulator of the cannabinoid receptor type 1 (CB1R) and adenosine monophosphate-activated protein kinase (AMPK), exhibiting a Ki of 0.81 nM and an IC50 of 3.9 nM for CB1R. This compound effectively activates AMPK, leading to significant reductions in food intake and body weight. Additionally, it enhances glucose tolerance and insulin sensitivity, making it a valuable tool for research in metabolic disorders and obesity-related studies. -
AMPK Activator
DBI-2 is an AMPK activator that targets mitochondrial complex I. It disrupts oxidative phosphorylation (OXPHOS), leading to a reduction in ATP generation within mitochondria. DBI-2 demonstrates significant inhibitory effects on the proliferation of colorectal cancer (CRC) cells, making it a valuable tool for investigating metabolic dysregulation in cancer research. -
AMPK Activator
BI-9774 is a potent activator of 5' AMP-activated protein kinase (AMPK), with an IC50 ranging from 12 to 88 nM. This compound is primarily utilized in research focused on metabolic disorders, such as type 2 diabetes and obesity, as well as in cardiovascular disease studies, including myocardial ischemia and heart failure. Its ability to modulate AMPK activity makes it a valuable tool for investigating therapeutic strategies in these areas. -
AMPK Activator
AMPK Activator 2, a fluorine-containing proguanil derivative, targets the AMP-activated protein kinase (AMPK) signaling pathway, enhancing its activation while downregulating the mTOR/4EBP1/p70S6K pathway. This compound exhibits significant anti-proliferative and anti-migratory effects on various human cancer cell lines, including UMUC3, T24, and A549. AMPK Activator 2 is valuable for research focused on cancer metabolism and therapeutic strategies aimed at metabolic regulation in oncology. -
AMPK Activator
AMPK activator 14 is a selective activator of AMP-activated protein kinase (AMPK). This compound has demonstrated the ability to lower fasted glucose and insulin levels in a db/db mouse model of Type II diabetes. It serves as a valuable tool for research into metabolic disorders and the mechanisms of diabetes management. -
AMPK-α1β1γ1 Activator
AMPK-α1β1γ1 activator 1 is a selective agonist for the AMPK-α1β1γ1 isoform, exhibiting an EC50 value of 38.1 nM. This compound serves as an acyl glucuronide metabolite of an Indole-3-carboxylic acid-based AMPK activator and demonstrates direct binding to the human AMPK complex. Its biological activity makes it a valuable tool for research into metabolic disorders such as diabetic nephropathy. -
AMPK Activator.
Galbacin, an AMPK activator, plays a crucial role in regulating cellular energy homeostasis. Isolated from Myristica fragrans (nutmeg), Galbacin effectively stimulates the AMPK enzyme in differentiated C2C12 cells, demonstrating notable anti-cancer properties by inhibiting the proliferation of lymphocytes and tumor cells. Additionally, it shows promise in preventing weight gain in diet-induced mice models, making it relevant for research into metabolic syndromes, including obesity and type 2 diabetes, as well as cancer studies. -
AMPK Activator
D942 is a potent activator of AMP-activated protein kinase (AMPK) that effectively penetrates cell membranes. This compound also exhibits partial inhibition of mitochondrial complex I. D942 has demonstrated significant anti-proliferative effects on multiple myeloma cells, making it a valuable tool for studies focusing on energy metabolism and cancer cell growth regulation. 연구 응용: D942 can be utilized in investigations of AMPK signaling pathways and their role in cancer metabolism. -
AMPK Activator
AMPK Activator 7 (compound I-3-24) is a potent activator of AMP-activated protein kinase (AMPK) with an EC50 value of 8.8 nM. This compound is valuable for investigating diseases linked to AMPK dysregulation, including type 2 diabetes, metabolic syndrome, obesity, hyperglycemia, hypercholesterolemia, and hypertension. Its selective activation of AMPK facilitates research into metabolic regulation and potential therapeutic interventions for these conditions. -
AMPK Activator
AMPK Activator 11 is a potent activator of AMP-activated protein kinase (AMPK) with nanomolar antiproliferative activity against various colorectal cancers (CRCs). By selectively activating AMPK, this compound enhances oxidative phosphorylation (OXPHOS) and inhibits the growth of RKO xenografts. AMPK Activator 11 is valuable for research in anti-tumor mechanisms and metabolic disease pathways. -
AMPK Regulator
4-PivO-NMT chloride is an indole-derived modulator of the AMPK signaling pathway, specifically influencing neurogenesis and neurite outgrowth by regulating AMPK activity. Its biological activity suggests potential applications in studying neurological disorders, pain mechanisms, and inflammatory responses. This compound serves as a valuable tool for researchers investigating the role of AMPK in various cellular processes. -
AMPK/Nrf2 Activator
Ethyl (E)-ferulate is an activator of the AMPK/Nrf2 signaling pathway, demonstrating significant potential in reducing acute lung injury induced by lipopolysaccharide. This compound exhibits antioxidant and free radical scavenging properties, contributing to its anti-inflammatory and neuroprotective effects. Ethyl (E)-ferulate is a valuable tool for research focused on inflammation and neurodegenerative diseases. -
AMPK Activator
AMPK activator C2 is a potent allosteric activator of AMP-activated protein kinase (AMPK). It enhances AMPK activity, which plays a critical role in cellular energy homeostasis and metabolic regulation. This compound is valuable for investigating the mechanisms underlying epilepsy and convulsions, contributing to the understanding of neuroenergetics and potential therapeutic approaches. -
AMPK Activator
IND 1316 is an orally active AMPK activator that effectively crosses the blood-brain barrier. It exhibits neuroprotective properties in preclinical models of Huntington's disease and is applicable in research concerning neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. This compound serves as a valuable tool for investigating AMPK-related pathways and therapeutic strategies in neurological diseases. -
PI4K Inhibitor
KAI-407 is an orally active inhibitor targeting Plasmodium PI4K kinase, effectively disrupting multiple stages of the parasite lifecycle. It demonstrates EC50 values of 81 nM against the blood stages of malignant Plasmodium and 88 nM for liver schizonts of P. yoelii. Additionally, KAI-407 exhibits IC50 values of 0.64 μM and 0.69 μM for liver schizonts and dormant bodies of P. cynomolgi, respectively. This compound is valuable for investigating vivax malaria and assessing potential therapeutic strategies against Plasmodium berghei infections. -
PI4K Inhibitor
BF738735 is a selective inhibitor of phosphatidylinositol 4-kinase III beta (PI4KIIIβ), exhibiting an IC50 of 5.7 nM. This compound effectively modulates lipid metabolism and signaling pathways involved in cellular processes. BF738735 is leveraged in research to investigate PI4KIIIβ's role in various diseases, including cancer and viral infections, highlighting its potential for therapeutic development. -
PI4KB Inhibitor
PI4K-IN-2 is a highly selective inhibitor of phosphatidylinositol 4-kinase β (PI4KB) with an IC50 of 0.015 μM. This compound demonstrates significant inhibitory activity and is particularly relevant for research involving human rhinovirus (HRV). Its potential applications extend to studies focusing on the role of PI4KB in viral replication and related signaling pathways. -
PI4KIIIα Inhibitor
GSK-A1 is a selective inhibitor of type III phosphatidylinositol 4-kinase PI4KIIIα, exhibiting a pIC50 of 8.5-9.8. It effectively inhibits the resynthesis of PtdIns(4,5)P2 with an IC50 of approximately 3 nM, leading to a potent decrease in PtdIns(4)P levels without significantly affecting PtdIns(4,5)P2. GSK-A1 serves as a valuable tool in research aimed at understanding its potential role in anti-hepatitis C virus (HCV) applications. -
PI4KIIIβ Inhibitor
MI 14 is a selective inhibitor of phosphatidylinositol 4-kinase III beta (PI4KIIIβ), demonstrating an IC50 of 54 nM for this target, while exhibiting limited activity against PI4KIIIα and PI4KIIα with IC50s greater than 100 μM. This compound displays notable antiviral efficacy against hepatitis C virus (HCV) genotype 1b, Coxsackievirus B3 (CVB3), human rhinovirus (HRV), and HCV genotype 2a. MI 14 serves as a valuable tool for research focused on viral pathogenesis and therapeutic interventions targeting lipid kinase signaling pathways. -
PI4KIIIα/HCV Inhibitor
AL-9 is a potent inhibitor of phosphatidylinositol 4-kinase III alpha (PI4KIIIα) with an IC50 of 0.57 μM. It effectively disrupts hepatitis C virus (HCV) replication, making it a valuable tool for studying viral pathogenesis and potential antiviral strategies. Its selective targeting of PI4KIIIα highlights its relevance in research applications focused on HCV infection and related therapeutic developments. -
mTOR Inhibitor
Aschantin is a bisepoxylignan that acts as a potent mTOR kinase inhibitor. This compound demonstrates significant biological activities, including antiplasmodial effects, calcium channel antagonism, and the inhibition of platelet activating factor. Additionally, Aschantin serves as an inhibitor of Cytochrome P450 and UGT enzymes, making it a valuable tool for chemoprevention research and various biochemical studies. -
mTORC1 Inhibitor
Sulindac sulfone is an mTORC1 pathway inhibitor and an active metabolite of Sulindac. It has been shown to effectively inhibit the growth of colon cancer cells and induce cell cycle arrest, making it a valuable tool in cancer research. This compound is primarily utilized to study the role of mTORC1 in tumorigenesis and to explore potential therapeutic strategies against colorectal cancer. -
Tubulin Polymerization/Akt Pathway Inhibitor
KS-99 is an inhibitor that targets both tubulin polymerization and the Akt signaling pathway. This compound demonstrates significant biological activity by inhibiting cancer cell proliferation and inducing apoptosis in various cancer cell types. KS-99 is suitable for research applications involving colorectal cancer, breast cancer, lung epithelial cancer, and melanoma. -
PI3Kα Inhibitor
VVD-442 is a selective inhibitor of PI3Kα that covalently binds to cysteine 242 within the RAS-binding domain of the PI3K p110α subunit. This binding induces conformational changes that disrupt the interaction between PI3K p110α and RAS proteins, effectively blocking RAS-mediated activation of PI3K. VVD-442 is applicable in research focusing on RAS-mutant cancers and HER2-overexpressing tumors, providing valuable insights into therapeutic strategies targeting these pathways. -
PI3Kδ Inhibitor
LAS195319 is a potent and orally active inhibitor of PI3Kδ, exhibiting an IC50 of 0.5 nM. This compound demonstrates high selectivity against a wide array of proteins, lipid kinases, and GPCRs. LAS195319 effectively inhibits the infiltration of neutrophils and eosinophils, making it a valuable tool for research into respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). -
PI3Kγ Inhibitor
SH-273 is a potent dual-function compound that acts as a selective inhibitor of PI3Kγ with an IC50 of 7 nM while also stimulating STING function with an EC50 of 100 nM. This unique profile makes SH-273 a valuable tool for investigating signaling pathways involved in pancreatic cancer. Researchers can utilize SH-273 to explore the therapeutic potential of targeting PI3Kγ and enhancing STING-mediated immune responses in cancer models. -
COX-2/PI3K Inhibitor
COX-2/PI3K-IN-2 is a potent inhibitor targeting both COX-2 and PI3K pathways, exhibiting an IC50 value of 2.78 nM for PI3K and a Ki value of 3.02 nM for COX-2. This compound demonstrates significant anti-inflammatory and anti-cancer activities, making it valuable for research in oncology and inflammatory disease studies. Its dual-target mechanism provides insights into the therapeutic potential of modulating these critical pathways. -
PI3K-δ/PI3K-γ inhibitor
IPI-145, also known as INK-1197, is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. -
AKT inhibitor
TIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. -
PDK1 Inhibitor
GSK 2334470 is a potent 3-phosphoinositide-dependent protein kinase (PDK1) inhibitor (IC50 ~ 10 nM). -
PI3K inhibitor
GDC-0032 is a potent, next-generation PI3 inhibitor targeting PI3 alpha. -
PI3K inhibitor
PF-4989216 is a potent and selective PI3K inhibitor with IC50 of 2 nM, 142 nM, 65 nM, 1 nM, and 110 nM for p110α, p110β, p110γ, p110δ, and VPS34, respectively.
